



Universiteit  
Leiden  
The Netherlands

## Studying the short-term complications of kidney transplantation: from bed to bench

Kok, M.J.C. de

### Citation

Kok, M. J. C. de. (2022, October 11). *Studying the short-term complications of kidney transplantation: from bed to bench*. Retrieved from <https://hdl.handle.net/1887/3479720>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3479720>

**Note:** To cite this publication please use the final published version (if applicable).



# Chapter 4

## **The neglectable impact of delayed graft function on long-term graft survival in kidneys donated after circulatory death associates with superior organ resilience**

Michèle J.C. de Kok, Dagmara McGuinness, Paul G. Shiels, Dorottya K. de Vries, Joanne B. Tutein Nolthenius, Leonie G.M. Wijermars, Ton J. Rabelink, Lars Verschuren, Karen S. Stevenson, David B. Kingsmore, Martin McBride, Rutger J. Ploeg, Esther Bastiaannet, Alexander F.M. Schaapherder, Jan H.N. Lindeman

*Annals of Surgery. 2019;270(5):877-883*

## Abstract

**Objective:** To explore putative different impacts of delayed graft function (DGF) on long-term graft survival in kidneys donated after brain death (DBD) and circulatory death (DCD).

**Background:** Despite a 3-fold higher incidence of DGF in DCD grafts, large studies show equivalent long-term graft survival for DBD and DCD grafts. This observation implies a differential impact of DGF on DBD and DCD graft survival. The contrasting impact is remarkable and yet unexplained.

**Methods:** The impact of DGF on DBD and DCD graft survival was evaluated in 6635 kidney transplants performed in The Netherlands. DGF severity and functional recovery dynamics were assessed for 599 kidney transplants performed at the Leiden Transplant Center. Immunohistochemical staining, gene expression profiling, and Ingenuity Pathway Analysis were used to identify differentially activated pathways in DBD and DCD grafts.

**Results:** While DGF severely impacted 10-year graft survival in DBD grafts (HR 1.67;  $P < 0.001$ ), DGF did not impact graft survival in DCD grafts (HR 1.08;  $P = 0.63$ ). Shorter dialysis periods and superior posttransplant eGFRs in DBD grafts show that the differential impact was not caused by a more severe DGF phenotype in DBD grafts. Immunohistochemical evaluation indicates that pathways associated with tissue resilience are present in kidney grafts. Molecular evaluation showed selective activation of resilience-associated pathways in DCD grafts.

**Conclusions:** This study shows an absent impact of DGF on long-term graft survival in DCD kidneys. Molecular evaluation suggests that the differential impact of DGF between DBD and DCD grafts relates to donor-type specific activation of resilience pathways in DCD grafts.

## Introduction

In an era of severe donor organ shortage and growing waiting lists for renal transplantation there is an increased reliance on expanded criteria donors and organs donated after circulatory death (DCD). While DCD donor kidneys constitute a large potential donor pool, higher incidences of primary non function and particularly delayed graft function (DGF) are regarded as major impediments.

Notwithstanding the higher incidence of DGF in DCD compared to donated after brain death (DBD) grafts, large cohort studies from the United Kingdom and The Netherlands show equivalent survival for kidneys DBD and DCD grafts.<sup>1-3</sup> This observation suggests a differential impact of DGF on DBD and DCD graft survival.

The apparent differential impact of DGF on DBD and DCD graft survival is remarkable and yet unexplained. One possible explanation for this phenomenon is that the type of DGF in DBD grafts reflects more severe transplantation-related injury. An alternative and mutually nonexclusive explanation is that the differential impact reflects differences in graft “resilience”—i.e. the ability of the graft to cope with negative environmental changes<sup>4</sup>—with DCD donor kidneys being more “resilient” than DBD grafts. Tissue resilience is an established phenomenon in cancer biology, and negatively associates with patient prognosis.<sup>4</sup> However, in the context of transplantation biology, resilience could be a beneficial factor potentially contributing to better transplantation outcomes.

Considering the emerging epidemiological evidence for a different impact of DGF on DBD and DCD graft survival and its clinical relevance, we have focused in this hypothesis generating study on this putative differential impact and also attempted to explore its biological basis.

## Materials and methods

### Study population

The impact of DGF (defined as the need for dialysis in the first postoperative week(s)) on long-term graft survival was evaluated in 6635 deceased donor kidney transplants performed between January 2000 and January 2018 in the Netherlands (Netherlands Organ Transplant Registry (NOTR)). Combined organ procedures, procedures in recipients younger than 12 years and uncontrolled circulatory death donor procedures were excluded.

The impact of donor type on DGF phenotype and functional recovery dynamics was assessed for 287 DBD and 312 DCD kidney transplants performed at the Leiden University Transplant Center between 2007 and 2018. A more detailed description of the methods is given in the Supplemental Data.

The clinical nomenclature and different phases included in this paper are illustrated in Figure 1.

### **Histology and gene expression**

Pre-reperfusion tissue biopsy samples from 80 donor kidneys were randomly selected based on donor type and the presence or absence of DGF (n = 20 per group, Supplemental Table 1). Immunohistochemical staining was performed for BCL2, IGF-1R, p53, PCNA, phospho-EGFR, phospho-MAPK14, phospho-mTOR, PPAR $\gamma$ . Details of the antibodies and procedures are summarized in the Supplemental Data and Supplemental Table 2.

Gene expression profiling of 23 DBD and 16 DCD pre-reperfusion renal biopsies was followed by Ingenuity Pathway Analysis (IPA, QIAGEN, USA) to identify differentially regulated pathways (Supplemental Table 3).<sup>5,6</sup>

All renal biopsies used in this study were collected after static cold storage, and prior to reperfusion. Further details of the analyses are provided in the Supplemental Data.

### **Statistical analysis**

STATA/SE version 12.0 (StataCorp, Texas) and IBM SPSS Statistics 23.0 (Amsterdam, The Netherlands) were used for statistical analysis. Comparisons between groups were analyzed using standard statistical methods. Cox proportional hazards models, adjusted for donor/recipient age and sex, and cold ischemic period were used to evaluate differences in impact of DGF on 10-year graft survival. Univariate analysis was followed by multivariate regression analysis to identify factors associated with DGF. A detailed description of the statistical analysis is given in the Supplemental Data.

## **Results**

### **Epidemiological evaluation**

Putative differential impacts of DGF on DBD and DCD graft survival were evaluated in 6635 kidney transplants (43.6% DCD procedures) that were performed between 2000 and 2018 in The Netherlands (Supplemental Table 4). The registry data confirmed a higher incidence of DGF in DCD grafts (DCD: 42.2% vs. DBD: 17.8%;  $P < 0.001$ ) but also showed differential impact of DGF on long-term graft survival per donor type. In fact, while DGF severely impacted 10-year graft survival in DBD donor kidneys [adjusted DGF-associated hazard ratio (aHR) for graft loss: 1.67 (95% CI 1.35–2.08);  $P < 0.001$ ], no impact on survival was observed for DGF in DCD donor kidneys [aHR for graft loss: 1.08 (95% CI 0.82–1.39);  $P = 0.63$ ]. Interaction testing confirmed the differential impact of DGF on DBD and DCD long-term graft survival ( $P$  for interaction  $< 0.001$ ).




Figure 1. The clinical nomenclature and different phases included in this paper.

The differential impact of DGF on long-term graft survival may relate to a greater threshold to develop DGF in DBD grafts (i.e., that development of DGF in DBD grafts requires a more severe

insult). This hypothesis was tested by using a qualitative and quantitative evaluation of risk factors associated with DGF. An inventory of risk factors associated with occurrence of DGF (multivariate analyses) revealed clearly qualitative differences between the 2 donor types. The first warm ischemic period, a discriminant factor of DCD grafts, was positively associated with DGF in DCD grafts. Both donor types shared cold ischemic period as a risk factor for developing DGF. Donor age was a significant risk factor for DBD grafts, but an association with DGF in DCD grafts did not reach statistical significance ( $P = 0.11$ ). The last serum creatinine value in the donor, human leukocyte antigen (HLA)-DR mismatch, and graft anastomosis time exclusively associated with DGF in DBD grafts but not in DCD grafts (Supplemental Table 5).

Quantitative analysis showed that DGF in recipients of DBD grafts was associated with a slightly unfavorable donor and procedural profile as reflected by the 2-year difference in donor age, higher donor serum creatinine concentrations, and 8% and 12% longer cold ischemic and graft anastomosis times (Table 1). However, this less favorable risk profile did not result in a more severe DGF phenotype in DBD grafts. On the contrary, recipients of DCD grafts with DGF required longer dialysis, and had profoundly inferior renal function (eGFR) in the first week following the last dialysis ( $P < 0.001$ ) (Table 2).

The above results did not point to a more profound DGF phenotype as underlying cause of the negative impact of DGF on long-term graft survival in DBD grafts. Alternatively, the differing impact may reflect differential resilience between the 2 donor types, with DCD grafts being more resilient than DBD grafts. A concept that is supported by the superior functional (eGFR) recovery dynamics in DCD grafts (Figure 2).

### **Histology and gene expression**

To explore the presence of resilient enhancing factors, we mapped several molecular upstream regulators associated with resilience in the context of tumor biology (e.g., p53, phospho-EGFR, IGF-1R, phospho-mTOR, phospho-MAPK14, PCNA, BCL2 and PPAR $\gamma$ ).<sup>7-13</sup> The immunohistochemical analysis demonstrated expression of the aforementioned resilience factors in pre-reperfusion kidney biopsies, indicating that aspects of the molecular mechanisms associated with tissue resilience are present in both donor types (Supplemental Figures 1 and 2).

With the aim of evaluating putative differential activation of molecular pathways associated with resilience in DBD and DCD grafts, an unbiased pathway analysis was



**Table 1. Comparison of risk factors associated with DGF in DBD and DCD graft recipients.**


	DBD DGF + n = 667	DCD DGF + n = 1219	p-value
Donor age (years)	52.1 (14.4)	50.2 (14.5)	0.006
Donor last creatinine ( $\mu\text{mol/L}$ )	77.0 [60.0–100.0]	68.0 [54.0–83.5]	< 0.001
Mismatch			0.004
HLA-DR 0	243 (36.5%)	362 (29.9%)	
1	360 (54.1%)	752 (62.0%)	
2	62 (9.3%)	98 (8.1%)	
Cold ischemic period (hours)	18.4 [14.4–23.0]	17.0 [13.1–21.0]	< 0.001
Graft anastomosis time (min.)	35.0 [26.0 – 42.0]	31.0 [25.0 – 40.0]	< 0.001

Data are presented as mean  $\pm$  standard deviation (SD) or as number (%) or as median [25 and 75 IQR].

**Table 2. DGF phenotype in DBD and DCD graft recipients.**


	DBD DGF + n = 80	DCD DGF + n = 179	p-value
Duration of dialysis (days)	7.5 [5.0–12.0]	9.0 [6.0–13.8]	0.039
Number of dialysis	3.5 [3.0–5.8]	4.0 [3.0–6.0]	0.462
First autonomous eGFR	20.3 [14.4–35.7]	13.4 [ 9.3–22.8]	< 0.001

Data are presented as median [25 and 75 IQR].

**Figure 2. Functional renal recovery (eGFR) after kidney transplantation.**

performed on the gene expression profiles in pre-reperfusion kidney biopsies from DBD and DCD donors. There were no differences in baseline characteristics between DBD and DCD donors (Supplemental Table 3, <http://links.lww.com/SLA/B725>). Using DBD grafts as the comparator, 6 differentially activated ( $P < 0.05$ ) upstream regulatory

pathways, and 13 differentially inhibited regulatory pathways were identified in DCD grafts (Figure 3). All upregulated pathways belonged to a family of factors responsible for renal development, cell fate, organogenesis, and stem cell maintenance. Pathways inhibited in DCD grafts included the p53 pathway, and a cluster of pro-inflammatory factors (IL6, TNF $\alpha$ , RANKL (TNFSF11), CEBP $\beta$ , TICAM1) (Figure 3). Functionally, the strongest influence was found by pathways associated with cardio-vascular diseases (P value range  $2.5 \times 10^{-10}$  to  $2.2 \times 10^{-3}$ ), in particular a gene cluster mapped by IPA as “advanced stage peripheral artery disease” (P value  $2.5 \times 10^{-10}$ ). This cluster is dominated by upregulation of heat shock proteins (Supplemental Figure 3).



**Figure 3. Differentially regulated upstream regulators in DBD and DCD donor kidneys based on Ingenuity Pathway Analysis (DBD is reference).**

BDNF (Brain-derived neurotrophic factor); BRCA1 (Breast cancer-associated gene 1); Bvht (Braveheart); CEBPB (CCAAT/Enhancer Binding Protein- $\beta$ ); EZH2 (Enhancer of zeste homolog 2); GMNN (Geminin); IL6 (Interleukin-6); PGR (Progesteron Receptor); RET (Rearranged during transfection); RETNLB (Resistin-like molecule  $\beta$ ); SLC13A1 (Solute carrier family 13 member 1); SMAD4 (Sma (*Caenorhabditis elegans*) Mothers Against Decapentaplegia homologue 4); SOX1 (Sex determining region Y-box protein 1); SOX3 (Sex determining region Y-box protein 3); TICAM1 (Toll Like Receptor Adaptor Molecule 1); TNF $\alpha$  (Tumor Necrosis Factor  $\alpha$ ); TNFSF11 (Tumor Necrosis Factor ligand Superfamily member 11); TP53 (Tumor Protein p53).

## Discussion

Whilst a high incidence of DGF after DCD kidney transplantation is considered a major obstacle toward a more liberal use of these grafts, recent epidemiological observations suggest that this concern might be unjustified. This integrative epidemiological and molecular analysis has clearly shown a differential impact of DGF on DBD and DCD graft survival, with no impact of DGF on DCD graft survival. This finding may reflect a more favorable baseline molecular resilience signature in DCD donor kidneys.

Transplants procedures with DCD donor kidneys are associated with a twofold to threefold increased incidence of DGF.<sup>2,3,14</sup> DGF is an established risk factor for premature graft loss, and as such the higher incidence of DGF with DCD grafts is considered a relative contra-indication for the use of DCD grafts by some transplant centers. This notion has recently been challenged by cohort studies showing equivalent graft survival for DBD and DCD grafts despite the difference in incidence of DGF: an observation that implies a differential impact of DGF on DBD and DCD graft survival. In this context it should be noted that the conclusions regarding the negative association between DGF and long-term outcomes are mainly based on studies from an era with an almost exclusive use of DBD grafts.<sup>15-19</sup> Moreover, it cannot be excluded that conclusions for DCD grafts are confounded by factors that relate to both DGF and graft survival.

The differential impact of DGF on graft survival was confirmed by the outcome data for almost 6,700 deceased donor kidney transplantations performed in The Netherlands, a country with a longstanding liberal tradition toward the use of DCD grafts (currently 50% of all deceased kidney transplantation procedures). While regression analysis confirmed the impact of DGF on long-term graft survival in DBD grafts, DGF did not affect graft survival in DCD grafts.

In an effort to understand the different impact of DGF on graft survival we first tested in this study whether the apparent impact on DBD grafts reflects the presence of a more severe DGF phenotype. This hypothesis was not supported by the clinical data. On the contrary, transplants with DCD grafts were hallmarked by a more severe graft injury as indicated by profoundly impaired posttransplant renal function (eGFR), and in case of DGF, a prolonged need for posttransplant dialysis. Irrespective of this, DCD grafts demonstrated an adequate functional recovery within weeks after transplantation, resulting in a renal function fully comparable to DBD grafts. The impact of DGF on ultimate eGFR was similar for DBD and DCD grafts. Thus, our clinical data do not support a more severe DGF phenotype as underlying cause of the negative impact of DGF in DBD grafts. In this light, we explored possible differences in graft resilience as an alternative explanation for the contrasting impact of DGF in DBD and DCD grafts.

Biologically, resilience is the ability of an organism to recover to normal functioning after perturbation.<sup>20</sup> In the context of ageing, resilience is the ability to cope with stress and re-establish homeostasis.<sup>21</sup> Tissue resilience is an established phenomenon in tumor biology, and a known negative prognostic factor.<sup>4</sup> In the context of organ transplantation, superior resilience would obviously be beneficial in terms of graft recovery and survival.

We applied gene expression profiling followed by pathway analysis to map putative molecular differences in organ resilience between DBD and DCD grafts. Pathways relatively enriched ( $n = 6$ ) in DCD grafts were all part of established resilience networks. Five upregulated pathways in DCD grafts (RET, Alpha catenin, GMNN, SOX1, and SOX3) were associated with renal development and cell proliferation, and partly associate with the Wnt/ $\beta$ -catenin signalling pathways:<sup>22–26</sup> a pivotal pathway in kidney development, repair, and regeneration.<sup>27–32</sup> The sixth upregulated pathway was the BRCA1 tumor suppressor pathway. BRCA1 is a key player in cellular repair through its role in DNA repair and cell cycle checkpoint activation. This pathway was recently shown to be cardioprotective after myocardial infarction.<sup>33</sup> In contrast to the BRCA-1 tumor suppressor pathway, we observed down-regulation of the p53 network. While this downregulation is considered a negative aspect in tumor biology, it has been pointed out that downregulation of p53 is part of the normal, physiological regenerative response, and as such, could be part of an activated resilience network.<sup>34</sup>

Downregulated pathways in DCD grafts were dominated by pro-inflammatory signaling cascades (i.e., IL6, TNF $\alpha$ , RANKL (TNFSF11), CEBP $\beta$ , TICAM1). This downregulation could be a consequence of an activated resilience network in DCD grafts. Other explanations included passive enrichment, reflecting differences in leucocyte influx (and thus genes associated with leucocytes) in DBD grafts,<sup>35</sup> as well as upregulation of parenchymal inflammation in response to brain death in DBD grafts.<sup>36</sup> It is unclear to what extent the relative downregulation of inflammatory responses in DCD grafts contributes to the absent impact of DGF in these grafts. Although inflammation is often seen as a “negative” factor, experimental data suggests that brain death-associated immune activation may not accelerate ischemia reperfusion injury<sup>37</sup> whereas other studies actually indicate aggravation of experimental ischemia reperfusion injury following interference with IL-6 or IL-9 signaling.<sup>35,38</sup>

A further observation is the downregulation of the BDNF signalling route in DCD grafts. Strong associations exist between BDNF and the kidney injury molecule (KIM-1), and BDNF has been recently proposed as a biomarker for glomerular injury.<sup>39</sup> As such, the relative downregulation of BDNF in DCD grafts might indicate that the glomerular injury is less in DCD than in DBD grafts.

On the functional level, the most influential transcriptomic signals were related to cardiovascular diseases, in particular “advanced stage peripheral artery disease.” This cluster is mainly comprised of members of heat shock protein superfamily. Induction of heat shock proteins following ischemia has been well documented. In the context of brain ischemia this was correlated with the regions that ultimately survived the injury,<sup>40</sup> suggesting that this superfamily is part of a resilience response.

Since all renal biopsies in this study were from grafts that were maintained on static cold storage (hence a state of absent transcriptional activity), the clear differences in gene expression profiles probably reflect donor-specific aspects such as brain death.<sup>41</sup> An alternative and nonexclusive explanation is that the activation of resilience pathways in DCD grafts is caused by a process of ischemic preconditioning that may occur during the agonal phase and first warm ischemic period prior to donor nephrectomy in DCD donors. Ischemic preconditioning, which generally refers to a preceding state of ischemia that is followed by reperfusion, is an established phenomenon in experimental studies.<sup>42–44</sup> Yet, studies so far do not indicate a benefit of ischemic preconditioning for clinical kidney injury.<sup>45</sup> It might be speculated that the ischemia applied in clinical studies is insufficient to induce activation of resilience pathways, and that more profound and localized triggers which occur during the agonal phase and first warm ischemic period in DCD donors are required.

Our study has several limitations. It is in part based on registry data including the standard flaws of a registry with some data missing and a lack of predefined variables, leading to more heterogeneity in data registration. Outcomes are prone to confounding by indication with some clinicians being more critical than others when accepting or declining DCD grafts for transplantation. Also, exploration of molecular mechanisms is based on observational data. A more detailed experimental exploration and validation of the observed differences is compromised by the profound species differences with regard to acute injury, ischemia reperfusion, and resilience.<sup>46,47</sup>

In conclusion, results in this clinically relevant study show that DGF has no obvious impact on long-term graft survival in DCD grafts. As such, the high incidence of DGF in DCD grafts should not be regarded a relative contraindication or impediment toward the use of these donor kidneys. The molecular evaluation performed suggests that the different impact of DGF in DBD and DCD grafts relates to donor type-specific regulation of resilience and pro-inflammatory pathways benefitting the DCD graft and its outcomes.

## Supplemental data

### Materials and methods

#### *Study population*

The impact of DGF on 10-year graft survival was evaluated in 6,635 deceased-donor kidney transplantations performed between 2000 and 2018 (Netherlands Organ Transplant Registry (NOTR)). Combined organ procedures, procedures in recipients younger than 12 years and uncontrolled circulatory death donor procedures were excluded.

The impact of DBD and DCD donor type on DGF phenotype and functional recovery dynamics was assessed for 287 DBD and 312 DCD kidney transplantations performed at the Leiden University Transplant Center between 2007 and 2018. In addition to previously described exclusion criteria, we excluded grafts with primary non-function. DGF was defined as the need for dialysis in the first postoperative week(s), followed by functional recovery and with exception of a single dialysis performed for elevated potassium levels or fluid overload. The MDRD (Modification of Diet in Renal Disease) Study equation was used to estimate glomerular filtration rate (eGFR). For recipients with DGF, the first autonomous eGFR ('week 1') was defined as the first week following last dialysis. Factors included in the DGF phenotype were duration of dialysis, number of dialysis and the first autonomous eGFR.

#### *Histology and gene expression*

Routine pre-reperfusion graft biopsies are used for graft quality control. All biopsies were collected after static cold storage, and prior to reperfusion. Biopsy samples from 80 donor kidneys were randomly selected based on donor type and the presence or absence of DGF (n=20 per group, Supplemental Table 1). One biopsy contained non-renal tissue and was excluded. Tissue sections (4µm) were cut and immunohistochemical staining was performed for BCL2, IGF-1R, p53, PCNA, phospho-EGFR, phospho-MAPK14, phospho-mTOR, PPARγ. Details of the antibodies and procedures are summarized in Supplemental Table 2. Anti-rabbit/mouse EnVision+ (Dako, Amstelveen, The Netherlands) and 3,3'-diaminobenzidine (DAB) substrate chromogen system (Dako, Amstelveen, The Netherlands) were used for antibody visualization. Tissue sections were counterstained with hematoxylin (Klinipath, Duiven, The Netherlands). All tissue sections were semi-quantitatively and independently reviewed by two observers (M.K. and J.T.N) and scored as: 0 (none), 1 (minimal), 2 (slight), 3 (moderate) and 4 (abundant). Scoring disagreements were identified and resolved by joint review to achieve consensus.

Gene expression profiling of pre-reperfusion renal biopsies and Ingenuity®Pathway Analysis (IPA®, QIAGEN, USA) was used to identify differentially regulated pathways in 23 DBD and 16 DCD grafts (Supplemental Table 3). All biopsies were collected after


static cold storage, and prior to reperfusion. Biopsies were either immediately snap frozen in liquid nitrogen or stabilized in RNAlater.<sup>5,6</sup> Samples were all stored at  $-80^{\circ}\text{C}$ . Total RNA was isolated from renal tissues using RNAzol (Campro Scientific, Vennendaal, The Netherlands)<sup>5</sup> or using TRI<sup>®</sup>Reagent according to the manufacturer's instructions (Invitrogen, UK),<sup>6</sup> cleaned and DNase treated (RNA Clean & Concentration, #R1015, Zymo Research, USA) then stored at  $-80^{\circ}\text{C}$  for further analysis. RNA integrity was determined (RNA Nano kit and 2100 BioAnalyzer, #5067–1511, Agilent Technologies, Inc. USA) and samples with  $\text{RIN} > 6.0$  were used for further analysis. Briefly, total RNA was used to create libraries using ribosomal depletion (TruSeq Stranded Total RNA Ribo-Zero H/M/R Gold, Illumina). Libraries were further assessed by Qubit<sup>®</sup> (Life Technologies, Inc. USA) and Bioanalyser (High Sensitivity DNA kit [#5067–4626, Agilent Technologies, Inc., USA]). Libraries were sequenced on a NextSeq500 (Illumina) using a paired-end  $2 \times 75$  bp run. Detailed methods and analysis approaches were described previously.<sup>6</sup> Raw count data were transformed to  $\log_2$  scale to normalize expression counts. Multiple testing correction was performed using the Benjamin–Hochberg approach to control false discovery rate (FDR) at 10% ( $\text{FDR} \leq 0.1$  was considered significant). Differentially expressed gene targets were analyzed using Ingenuity<sup>®</sup>Pathway Analysis (IPA<sup>®</sup>, QIAGEN, USA).

### *Statistical analysis*

STATA/SE version 12.0 (StataCorp, Texas, USA) and IBM SPSS Statistics 23.0 (Amsterdam, The Netherlands) were used for statistical analysis. Comparisons between groups were performed using the Mann-Whitney rank test and Kruskal-Wallis test for non-parametric data, independent t-test for normal-distributed data, and the Chi-Square test for categorical data. Cox proportional hazards models, censored for early graft loss (defined as functional graft loss within 90 days after transplantation) and recipient death, were used to evaluate differences in impact of DGF on 10-year graft survival. The model adjusted for donor/recipient age and sex, and cold ischemic period. An interaction (Wald) test was used to test the differences between the two models in DCD and DBD grafts. Factors associated with DGF were identified by multivariate regression analysis. The model included all variables with a p-value  $< 0.10$  in the univariate analysis. P-values  $< 0.05$  were considered statistically significant.

## **Acknowledgements**


The authors gratefully acknowledge the Dutch Transplant Foundation (Nederlandse Transplantatie Stichting) for providing the data.



**Supplemental Figure 1. Immunohistochemical scoring of pre-reperfusion kidney biopsies. Bars represent mean  $\pm$  standard deviation.**

Expression of BCL2 (Kruskal-Wallis test  $p = 0.653$ ), IGF-1R ( $p = 0.340$ ), p53 ( $p = 0.268$ ), PCNA ( $p = 0.846$ ), phospho-MAPK14 ( $p = 0.510$ ), phospho-mTOR ( $p = 0.554$ ), PPAR $\gamma$  ( $p = 0.350$ ) did not differ between groups. Expression of phospho-EGFR was lower in DCD grafts without DGF ( $p = 0.002$ ).





**Supplemental Figure 2. Immunohistochemical staining of pre-reperfusion kidney biopsies for factors associated with tumor resilience.** Bars represent 100μm.

*A = BCL-2; B = IGF-1R; C = p53; D = PCNA; E = phospho-EGFR; F = phospho-MAPK14; G = phospho-mTOR; H = PPARγ.*



**Supplemental Table 1. Patient and transplant characteristics of the biopsies used for immunohistochemical evaluation.**

		DBD DGF - n = 20	DBD DGF + n = 20	DCD DGF - n = 20	DCD DGF + n = 19	p- value
<b>Donor</b>	Age (years)	55 [49-63]	58 [44-64]	61 [52-64]	63 [52-65]	0.53
	Sex (% male)	11 (55%)	9 (45%)	12 (60%)	11 (58%)	0.79
<b>Recipient</b>	Age (years)	58 [46-69]	54 [44-67]	65 [54-69]	55 [46-73]	0.42
	Sex (% male)	10 (50%)	10 (50%)	16 (80%)	15 (79%)	0.06
<b>Transplant</b>	First warm ischemic period (min.)	NA	NA	14 [12-17]	16 [13-18]	0.28
	Cold ischemic period (hours)	10.7 [8.6–14.0]	14.9 [8.9–18.5]	11.7 [10.3–13.9]	12.1 [10.2–15.8]	0.31
	Graft anastomosis time (min.)	29 [22-33]	33 [28-38]	32 [27-37]	31 [23-38]	0.36
	Number of dialysis after transplantation	NA	4 [2-5]	NA	5 [3-7]	0.09

Data are presented as number (%) or as median [25 and 75 IQR]. NA: not applicable.

**Supplemental Table 2. Details of antibodies used in this study.**

Primary Antibody	Clone	Source	Retrieval	Dilution	Manufacturer	Catalog no.
BCL2	124	Monoclonal mouse	Tris EDTA	1:300	Dako	M0887
IGF-1R	3G5C1	Monoclonal mouse	Citrate	1:1000	ThermoFisher Scientific	MA5-15354
P53	DO-7	Monoclonal mouse	Tris EDTA	1:50	ThermoFisher Scientific	MA5-12557
PCNA	PC10	Monoclonal mouse	Citrate	1:300	ThermoFisher Scientific	13-3900
Phospho-EGFR	S.684.2	Monoclonal mouse	Tris EDTA	1:900	ThermoFisher Scientific	MA-15199
Phospho-MAPK14	-	Polyclonal rabbit	Citrate	1:300	Merck	SAB4300201
Phospho-mTOR	Ser 2481	Monoclonal mouse	Citrate	1:100	SantaCruz Biotechnology	Sc-293089
PPAR $\gamma$	-	Polyclonal rabbit	Citrate	1:300	Bio-Rad	AHP1461

**Supplemental Table 3. Patient and transplant characteristics of the biopsies used for gene expression profiles and Ingenuity Pathway Analysis.**

		DBD n = 23	DCD n = 16	p-value
<b>Donor</b>	Age (years)	54.2 (15.7)	47.8 (15.8)	0.22
	Sex (% male)	11 (47.8%)	7 (43.8%)	0.70
<b>Recipient</b>	Age (years)	53.7 (12.9)	58.3 (8.3)	0.23
	Sex (% male)	12 (52.2%)	11 (68.8%)	0.38
<b>Transplant</b>	Cold ischemic period (hours)	12.5 [9.4–16.8]	11.6 [8.8–15.3]	0.51
	Graft anastomosis time (min.)	31.5 [24.8–33.5]	28.5 [24.0–30.8]	0.40
	Delayed graft function (% yes)	7 (30.4%)	12 (75.0%)	0.02

Data are presented as mean  $\pm$  standard deviation (SD) or as number (%) or as median [25 and 75 IQR].

**Supplemental Table 5. Multivariate analysis (Odds Ratio (95% CI)): risk factors associated with DGE.**

	<b>DBD</b>	<b>DCD</b>
Donor age	1.012 (1.005–1.019)**	1.006 (0.999–1.012)
Donor last creatinine ( $\mu\text{mol/L}$ )	1.008 (1.006–1.010)**	1.000 (0.996–1.003)
Mismatch HLA-DR	1.215 (1.036–1.426)*	1.168 (0.992–1.357)
First warm ischemic period (min.)	NA	1.017 (1.004–1.031)*
Cold ischemic period (hours)	1.035 (1.021–1.049)**	1.019 (1.002–1.036)*
Graft anastomosis time (min.)	1.017 (1.010–1.024)**	0.996 (0.989–1.003)

\* $p < 0.05$ ; \*\*  $p < 0.005$ , NA: not applicable.

**Supplemental Table 4. Baseline patient and transplant characteristics.**

		<b>DBD</b> <b>n = 3744 (56.4%)</b>	<b>DCD</b> <b>n = 2891 (43.6%)</b>	<b>p-value</b>
<b>Donor</b>	Age (years)	50.0 (15.0)	49.6 (15.0)	0.261
	Sex (% male)	1783 (47.6%)	1682 (58.2%)	< 0.001
	Height (cm)	173.0 (9.9)	175.0 (10.3)	< 0.001
	Weight (kg)	76.0 (15.6)	77.9 (16.7)	< 0.001
	BMI (kg/m <sup>2</sup> )	25.3 (4.3)	25.3 (4.6)	0.648
	Last creatinine (μmol/L)	70.7 [56.0–91.0]	67.0 [53.0–83.0]	< 0.001
	Cause of death			< 0.001
	- Trauma	736 (19.7%)	806 (27.9%)	
	- Stroke	2241 (59.9%)	1123 (38.8%)	
	- Cardiac arrest	124 (3.3%)	418 (14.5%)	
	- Other	643 (17.2%)	544 (18.8%)	
	Hypertension (% yes)	984 (30.1%)	579 (21.1%)	< 0.001
	Diabetes (% yes)	168 (6.2%)	149 (5.7%)	0.407
	Smoking (% yes)	1760 (51.4%)	1378 (50.6%)	0.492
<b>Recipient</b>	Age (years)	52.1 (14.6)	54.1 (13.3)	< 0.001
	Sex (% male)	2170 (58.0%)	1806 (62.5%)	< 0.001
	Height (cm)	170.7 (10.2)	171.8 (10.3)	< 0.001
	Weight (kg)	73.9 (15.4)	76.7 (15.4)	< 0.001
	BMI (kg/m <sup>2</sup> )	25.3 (4.5)	26.0 (4.4)	< 0.001
	Pre-emptive (% yes)	62 (1.7%)	57 (2.0%)	0.333
	Panel reactive antibodies			< 0.001
	- PRA <6%	3172 (84.7%)	2640 (91.3%)	
	- PRA ≥6 and <85	496 (13.3%)	235 (8.1%)	
	- PRA ≥85	75 (2.0%)	16 (0.6%)	
	Mismatches			
	HLA-DR 0	1558 (41.7%)	922 (32.1%)	< 0.001
	1	1883 (50.4%)	1718 (59.8%)	< 0.001
	2	292 (7.8%)	231 (8.0%)	< 0.001
	HLA-A 0	1451 (38.9%)	878 (30.4%)	
	1	1828 (49.0%)	1577 (54.7%)	
	2	455 (12.2%)	429 (14.9%)	
HLA-B 0	978 (26.2%)	476 (16.5%)		
1	1873 (50.2%)	1706 (59.2%)		
2	883 (23.6%)	702 (24.3%)		
<b>Transplant</b>	First warm ischemic period (min.)	NA	17.0 [14.0–21.0]	NA
	Cold ischemic period (hours)	17.0 [13.1 – 22.0]	16.0 [12.6 – 20.1]	< 0.001
	Graft anastomosis time (min.)	34.0 [26.0 – 41.0]	32.0 [26.0 – 40.0]	0.003

Data are presented as mean (± standard deviation) or as number (%) or as median [25 and 75 IQR]. NA: not applicable.

## References

1. Summers DM, Johnson RJ, Allen J, et al. Analysis of factors that affect outcome after transplantation of kidneys donated after cardiac death in the UK: a cohort study. *Lancet*. 2010;376:1303–1311.
2. Summers DM, Watson CJ, Pettigrew GJ, et al. Kidney donation after circulatory death (DCD): state of the art. *Kidney Int*. 2015;88:241–249.
3. Schaapherder AF, Wijermars LGM, de Vries DK, et al. Equivalent long-term transplantation outcomes for kidneys donated after brain death and cardiac death: conclusions from a nationwide evaluation. *EclinicalMedicine*. 2018;4:25–31.
4. Smirnova L, Harris G, Leist M, et al. Cellular resilience. *ALTEX*. 2015;32:247–260.
5. Wijermars LG, Schaapherder AF, de Vries DK, et al. Defective postreperfusion metabolic recovery directly associates with incident delayed graft function. *Kidney Int*. 2016;90:181–191.
6. McGuinness D, Mohammed S, Monaghan L, et al. A molecular signature for delayed graft function. *Aging Cell*. 2018;17:e12825.
7. Kasthuber ER, Lowe SW. Putting p53 in Context. *Cell*. 2017;170:1062–1078.
8. Van der Veecken J, Oliveira S, Schiffelers RM, et al. Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy. *Curr Cancer Drug Targets*. 2009;9:748–760.
9. Wullschlegel S, Loewith R, Hall MN. TOR signaling in growth and metabolism. *Cell*. 2006;124:471–484.
10. Dhillon AS, Hagan S, Rath O, et al. MAP kinase signalling pathways in cancer. *Oncogene*. 2007;26:3279–3290.
11. Wang SC. PCNA: a silent housekeeper or a potential therapeutic target? *Trends Pharmacol Sci*. 2014;35:178–186.
12. Yip KW, Reed JC. Bcl-2 family proteins and cancer. *Oncogene*. 2008;27:6398–6406.
13. Tachibana K, Yamasaki D, Ishimoto K, et al. The role of PPARs in cancer. *PPAR RES*. 2008;2008:102737.
14. Singh RP, Farney AC, Rogers J, et al. Kidney transplantation from donation after cardiac death donors: lack of impact of delayed graft function on posttransplant outcomes. *Clin Transplant*. 2011;25:255–264.
15. Sanfilippo F, Vaughn WK, Spees EK, et al. The detrimental effects of delayed graft function in cadaver donor renal transplantation. *Transplantation*. 1984;38:643–648.
16. Nicholson ML. Renal transplantation from non-heart-beating donors. *Br J Surg*. 1996;83:147–148.
17. Yokoyama I, Uchida K, Kobayashi T, et al. Effect of prolonged delayed graft function on long-term graft outcome in cadaveric kidney transplantation. *Clin Transplant*. 1994;8:101–106.
18. Pfaff WW, Howard RJ, Patton PR, et al. Delayed graft function after renal transplantation. *Transplantation*. 1998;65:219–223.
19. Feldman HI, Gayner R, Berlin JA, et al. Delayed function reduces renal allograft survival independent of acute rejection. *Nephrol Dial Transplant*. 1996;11:1306–1313.

20. Scheffer M, Bolhuis JE, Borsboom D, et al. Quantifying resilience of humans and other animals. *Proc Natl Acad Sci U S A*. 2018;115:11883–11890.
21. Kirkland JL, Stout MB, Sierra F. Resilience in aging mice. *J Gerontol A Biol Sci Med Sci*. 2016;71:1407–1414.
22. Kormish JD, Sinner D, Zorn AM. Interactions between SOX factors and Wnt/beta-catenin signaling in development and disease. *Dev Dyn*. 2010;239:56–68.
23. Tsao CM, Yan MD, Shih YL, et al. SOX1 functions as a tumor suppressor by antagonizing the WNT/b-catenin signaling pathway in hepatocellular carcinoma. *Hepatology*. 2012;56:2277–2287.
24. Daugherty RL, Serebryanny L, Yemelyanov A, et al. a-Catenin is an inhibitor of transcription. *Proc Natl Acad Sci U S A*. 2014;111:5260–5265.
25. Dudderidge TJ, Stoeber K, Loddo M, et al. Mcm2, Geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma. *Clin Cancer Res*. 2005;11:2510–2517.
26. Wang Y, Stokes A, Duan Z, et al. Receptor-related protein 6 modulates ret proto-oncogene signaling in renal development and cystic dysplasia. *J Am Soc Nephrol*. 2016;27:417–427.
27. Orlando G, Danger R, Okut H, et al. Molecular pathways underlying adaptive repair of the injured kidney: novel donation after cardiac death and acute kidney injury platforms. *Ann Surg*. 2020;271:383–390.
28. Little MH, Kairath P. Does renal repair recapitulate kidney development? *J am Soc Nephrol*. 2017;28:34–46.
29. Pulkkinen K, Murugan S, Vainio S. Wnt signaling in kidney development and disease. *Organogenesis*. 2008;4:55–59.
30. Zhou D, Tan RJ, Fu H, et al. Wnt/b-catenin signaling in kidney injury and repair: a double-edged sword. *Lab Invest*. 2016;96:156–167.
31. Lin SL, Li B, Rao S, et al. Macrophage Wnt7b is critical for kidney repair and regeneration. *Proc Natl Acad Sci U S A*. 2010;107:4194–4199.
32. Kuncewitch M, Yang WL, Corbo L, et al. Agonist decreases tissue damage and improves renal function after ischemia-reperfusion. *Shock*. 2015;43:268–275.
33. Shukla PC, Singh KK, Quan A, et al. BRCA1 is an essential regulator of heart function and survival following myocardial infarction. *Nat Commun*. 2011;2:593.
34. Charni M, Aloni-Grinstein R, Molchadsky A, et al. p53 on the crossroad between regeneration and cancer. *Cell Death Differ*. 2017;24:8–14.
35. de Vries DK, Lindeman JH, Ringers J, et al. Donor brain death predisposes human kidney grafts to a proinflammatory reaction after transplantation. *Am J Transplant*. 2011;11:1064–1070.
36. Bouma HR, Ploeg RJ, Schuurs TA. Signal transduction pathways involved in brain death-induced renal injury. *Am J Transplant*. 2009;9:989–997.
37. Ritschl PV, Ashraf MI, Oberhuber R, et al. Donor brain death leads to differential immune activation in solid organs but does not accelerate ischaemia-reperfusion injury. *J Pathol*. 2016;239:84–96.
38. Kortekaas KA, de Vries DK, Reinders ME, et al. Interleukin-9 release from human kidney grafts and its potential protective role in renal ischemia/reperfusion injury. *Inflamm Res*. 2013;62:53–59.



39. Endlich N, Lange T, Kuhn J, et al. BDNF: mRNA expression in urine cells of patients with chronic kidney disease and its role in kidney function. *J Cell Mol Med*. 2018;22:5265–5277.
40. Stetler RA, Gan Y, Zhang W, et al. Heat shock proteins: cellular and molecular mechanisms in the central nervous system. *Prog Neurobiol*. 2010;92:184–211.
41. McGuinness D, Leierer J, Shapter O, et al. Identification of molecular markers of delayed graft function based on the regulation of biological ageing. *PLoS One*. 2016;11:e0146378.
42. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. *Circulation*. 1986;74:1124–1136.
43. Yin DP, Sankary HN, Chong AS, et al. Protective effect of ischemic preconditioning on liver preservation-reperfusion injury in rats. *Transplantation*. 1998;66:152–157.
44. Chen X, Liu X, Wan X, et al. Ischemic preconditioning attenuates renal ischemia-reperfusion injury by inhibiting activation of IKKbeta and inflammatory response. *Am J Nephrol*. 2009;30:287–294.
45. Menting TP, Wever KE, Ozdemir-van Brunschot DM, et al. Ischaemic preconditioning for the reduction of renal ischaemia reperfusion injury. *Cochrane Database Syst Rev*. 2017;3:CD010777.
46. Seok J, Warren HS, Cuenca AG, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. *Proc Natl Acad Sci U S A*. 2013;26:3507–3512.
47. Wijermars LG, Schaapherder AF, Kostidis S, et al. Succinate accumulation and ischemia-reperfusion injury: of mice but not men, a study in renal ischemia-reperfusion. *Am J Transplant*. 2016;16:2741–2746.

